Evidence map›Paper›PMID 30565858›Full record

ArticleJournal of cellular and molecular medicine2019

LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis.

Meng Wu, Yawei Huang, Tongchang Chen, Weichao Wang, Shiguang Yang, Zhenfeng Ye, Xiaoqing Xi

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 1 synthesis or guideline pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Estradiol Promotes Endometriosis ProgressionCurrent pharmaceutical biotechnology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. mJournal of translational medicine · 2024
    Article
  19. Article
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Meng WuDepartment of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Yawei HuangDepartment of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Tongchang ChenDepartment of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Weichao WangDepartment of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Shiguang YangDepartment of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Zhenfeng YeDepartment of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Xiaoqing XiDepartment of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.ORCID 0000-0002-4545-5768
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was designed to detecting the influences of lncRNA MEG3 in prostate cancer. Aberrant lncRNAs expression profiles of prostate cancer were screened by microarray analysis. The qRT-PCR and Western blot were employed to investigating the expression levels of lncRNA MEG3, miR-9-5p and QKI-5. The luciferase reporter assay was utilized to testifying the interactions relationship among these molecules. Applying CCK-8 assay, wound healing assay, transwell assay and flow cytometry in turn, the cell proliferation, migration and invasion abilities as well as apoptosis were measured respectively. LncRNA MEG3 was a down-regulated lncRNA in prostate cancer tissues and cells and could inhibit the expression of miR-9-5p, whereas miR-9-5p down-regulated QKI-5 expression. Overexpressed MEG3 and QKI-5 could decrease the abilities of proliferation, migration and invasion in prostate cancer cells effectively and increased the apoptosis rate. On the contrary, miR-9-5p mimics presented an opposite tendency in prostate cancer cells. Furthermore, MEG3 inhibited tumour growth and up-regulated expression of QKI-5 in vivo. LncRNA MEG3 was a down-regulated lncRNA in prostate cancer and impacted the abilities of cell proliferation, migration and invasion, and cell apoptosis rate, this regulation relied on regulating miR-9-5p and its targeting gene QKI-5.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression ProfilingHumansMaleMice, Inbred BALB CMice, NudeMicroRNAsPC-3 CellsProstatic NeoplasmsRNA-Binding ProteinsMEG3 non-coding RNA, humanMicroRNAsMIRN92 microRNA, humanRNA-binding protein QKI-5, humanRNA-Binding ProteinsRNA, Long NoncodinglncRNA MEG3miR-9-5pprostate cancerQKI-5

Identifiers

PMID30565858
PMCPMC6307767
OpenAlexW2904953089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.